Category: News

Sustained-release drug delivery targets pediatric inherited retinal disease For many children, inherited retinal diseases begin early in life, slowly taking away vision with no approved drug therapies available to slow or stop the damage. PolyActiva and RareSight are now working together to address that, collaborating on the development of first-in-class pharmacologic treatments for rare pediatric inherited..

The AlmanacEntrepreneur Pushes for New Treatments for Childhood Eye DiseasesAuthor: Arden Margulis ‘Kids get the leftovers …I thought it’s backwards,’ Caricchio said. Carmen Caricchio is a Menlo Park resident who founded RareSight, which aims to find a treatment for childhood inherited retinal diseases. Courtesy Carmen Caricchio. Menlo Park resident Carmen..

Market Scope PolyActiva, RareSight to Collaborate on Rare Pediatric Retinal DiseasesAuthor: Jennie Crabbe Australia’s PolyActiva announced Nov. 5 that it would collaborate with RareSight, of Menlo Park, California, an ophthalmology-focused life sciences company committed to advancing therapies for rare pediatric retinal diseases. The collaboration will leverage PolyActiva’s Prezia sustained-release intravitreal drug..

Eyes On Eyecare GlancePolyActiva and RareSight to advance long-acting therapies for pediatric IRDsAuthor: Alex Delaney-Gesing PolyActiva is collaborating with RareSight, Inc. to develop targeted therapeutics specifically designed for rare pediatric retinal diseases with no currently-approved treatments. First, a look at RareSight. This ophthalmic-based life sciences company is focused on accelerating the diagnosis..

In a move that could reshape how IRDs are treated, two innovative companies are joining forces to make long-lasting vision therapies a reality. 

PolyActiva (Victoria, Australia) and RareSight (California, USA) have announced a strategic collaboration to co-develop sustained-release therapies for rare pediatric retinal diseases, marking PolyActiva’s expansion into new ophthalmic indications beyond glaucoma.

Australian biotech PolyActiva and USA-based RareSight have formed a strategic collaboration to create first-in-class treatments for inherited retinal diseases in children. The research will apply PolyActiva’s proprietary Prezia sustained-release platform to generate new pro-drugs that can be delivered directly to the retina.

PolyActiva and RareSight announced a strategic collaboration to develop first-in-class therapies for rare pediatric retinal diseases currently lacking approved drug treatments. The collaboration leverages PolyActiva’s PREZIA platform to create sustained-release, intravitreally administered treatments that deliver medication directly to the retina without requiring patient administration—a benefit for children and caregivers.

PolyActiva, which has a novel drug delivery technology to improve outcomes for patients with ocular conditions, has entered into a strategic collaboration with RareSight to advance therapies for rare pediatric retinal diseases that currently have no approved drug treatments.

November 5, 2025Contract Pharma By: Charlie SternbergPolyActiva, RareSight Partner to Develop Therapies for Rare Pediatric Retinal Diseases PolyActivaSearch company, a clinical-stage biopharmaceutical company, and RareSightSearch company, Inc., an ophthalmology-focused life sciences company, have announced a strategic collaboration to develop first-in-class therapies for rare pediatric retinal diseasesSearch disease that currently have no approved drug treatments…

Polyactiva Pty Ltd., of Melbourne, Australia, and Raresight Inc., of Menlo Park, Calif., reported a strategic collaboration to develop first-in-class therapies for rare pediatric retinal diseases that currently have no approved drug treatments.